daclizumab

Type: Product
Name: daclizumab
First reported 25 mins ago - Updated 25 mins ago - 1 reports

Multiple Sclerosis: New Treatments, Tough Decisions

Andrew N. Wilner, MD: I am Dr Andrew Wilner, and I am here today with Dr Stephen Krieger, Assistant Professor of Neurology and Director of the Neurology Resident Program at the Icahn School of Medicine at Mount Sinai Medical Center in New York City. Welcome, ... [Published Diabetes Care - 25 mins ago]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Biogen Idec Offers Growth Investors An Attractive Entry Point

Summary Biogen Idec reported strong second quarter earnings on July 23rd. Biogen Idec increased its full year 2014 forward guidance. Following the strong second quarter results, analysts have revised their estimates higher for both this fiscal year ... [Published Seeking Alpha - Sep 22 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

ACTRIMS/ECTRIMS Summary

17 September 2014Author:A review of some of the research from the recent ACTRIMS / ECTRIMS conference, including daclizumab, generic glatiramer acetate, a fingolimod similar, body temperature, cholesterol, comorbidities, stem cells, cognition, genetics, ... [Published Multiple Sclerosis Trust - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Regeneron's Eylea scores Breakthrough label

Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one ...Analysts do not expect odanacatib to be a major earner.Phase-III results of ... [Published Medical Marketing And Media - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

ECTRIMS 2014: Daclizumab results

Daclizumab was my number 1 ECTRIMS highlight: what is it telling us about MS?  #MSBlog #MSResearch "My number one ECTRIMS highlight is the MRI daclizumab results, which shows that daclizumab reduces brain atrophy compared to Avonex in both year 1 and ... [Published Multiple Sclerosis Research - Sep 17 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Daclizumab HYP a new kid on the block

Othman AA, Tran JQ, Tang MT, Dutta S. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration.  Clin Pharmacokinet. 2014 Sep 12. ... [Published Multiple Sclerosis Research - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More

It’s back to work, back to school, and back to the grind in biotech. One local company inched towards a potential FDA approval, yet its stock is down more than 10 percent. Another biotech came under fire for a big price hike on an old drug. And a new ... [Published Xconomy - Sep 15 2014]
First reported Sep 14 2014 - Updated Sep 14 2014 - 1 reports

EBV and HHV-6 reactive cells concentrated in the CNS

Is MS caused by a virus? T cells reactive againts HHV-6 and EBV may provide a clue. #MSBlog #MSResearch "The study below suggests that T cells responding to specific herpes viruses are enriched in the spinal fluid of MSers and not T cells responding ... [Published Multiple Sclerosis Research - Sep 14 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 4 reports

AbbVie and Biogen inch toward the FDA with once-a-month MS drug

Partners Biogen Idec ($BIIB) and AbbVie ($ABBV) are touting late-stage results for their new, monthly multiple sclerosis treatment, preparing to hand in regulatory applications next year and contend in a crowded market.The drug, daclizumab, is a subcutaneous ... [Published FierceBiotech - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry

BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head ag ... [Published MedPageToday.com - medical news plus CME for ph ... - Sep 12 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

5 Things Biogen Idec Inc's Management Wants You to Know

Biogen Idec ( NASDAQ: BIIB     ) held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ).George ... [Published Motley Fool Discussion Boards - Sep 03 2014]
First reported Jun 16 2014 - Updated Jun 17 2014 - 4 reports

Another eagle has landed: phase 3 daclizumab trial is positive

Daclizumab: another repurposed drug resurfaces as a treatment for MS #MSBlog #MSResearch Press Release Biogen-Idec and Abbvie have announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority ... [Published Multiple Sclerosis Research - Jun 16 2014]

Quotes

As used herein, the term "disruption of the flow of blood in or around the brain" in the context of treatment of such a disruption, encompasses treatment of one or more symptoms exhibited by an individual having the disruption and...
"A much larger and more definitive study is Maria-Pia Sormani's meta-analysis  of 13 phase 3 trials with over 13,500 study subjects. She showed a strong correlation between both T2 volume and brain atrophy in year 2 and EDSS progression over 2 years. What is remarkable is that when you combined these two metrics together you got a R-squared value of 0.75; in statistical terms R is the correlation coefficient and R-squared the variance of the correlation. What does this mean? It means that 75% of the variance of EDSS progression can be explained by T2 lesions and brain atrophy in year two. Therefore if you can stop all new T2 lesions forming and normalise brain atrophy rates in year two you will reduce disease progression by at least 75%. This study is very important as it gets to the heart of treating MS effectively; to do so we need to used DMTs that suppress both T2 lesions (focal inflammatory events) as much as possible and also reduce brain atrophy rates to near 'normal' in year 2. In reality there are only three treatments that do this currently, natalizumab, alemtuzumab and bone marrow transplantation.  The other treatments with a significant impact on both T2-lesions and brain atrophy are fingolimod and daclizumab (yet to be licensed), but they are not as effective as the three big guns. Interestingly, interferon-beta-1a (Avonex) is the only drug in the moderate efficacy band that impacts brain atrophy. Why Avonex and not the other interferons do this is an interesting point and may have to do with the fact that Avonex is a pulsed interferon and the others interferon's continuously stimulate the interferon receptor. It will be interesting to see what happens to brain atrophy with pegylated interferon-beta-1a? I suspect it won't have an impact on brain atrophy as it is also an interferon that stimulates the receptor continuously."
"The results from DECIDE further support the potential of ZINBRYTA and we look forward to submitting the data for this investigational therapy to regulatory agencies" said Michael Severino, M D , executive vice president, Research and Development and chief scientific officer, AbbVie
...We simply can't ignore Daclizumab's putative mode of action; it is telling us something very important about MS. "The great tragedy of science - the slaying of a beautiful hypothesis by an ugly fact."  Thomas Huxley

More Content

All (47) | News (20) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Multiple Sclerosis: New Treatments, Tough Decis... [Published Diabetes Care - 25 mins ago]
Uveitis in Multiple Sclerosis, What To Do [Published EMax Health - Sep 26 2014]
Treatment of stroke using isolated placental cells [Published PharmCast - Sep 23 2014]
Biogen Idec Offers Growth Investors An Attracti... [Published Seeking Alpha - Sep 22 2014]
ClinicSpeak: MS phenotypes by MRI [Published Multiple Sclerosis Research - Sep 20 2014]
Biogen Idec Announces Strides In Clinical Studi... [Published Bioresearch Online - Sep 18 2014]
ACTRIMS/ECTRIMS Summary [Published Multiple Sclerosis Trust - Sep 18 2014]
Biogen and AbbVie report reduced disease activi... [Published Pharma Letter - Sep 18 2014]
Biogen Idec and AbbVie Issues Phase 3 Decide St... [Published Individual.com - Sep 17 2014]
ECTRIMS 2014: Daclizumab results [Published Multiple Sclerosis Research - Sep 17 2014]
Regeneron's Eylea scores Breakthrough label [Published Medical Marketing And Media - Sep 17 2014]
Daclizumab HYP a new kid on the block [Published Multiple Sclerosis Research - Sep 16 2014]
AbbVie, Biogen to file MS drug next year [Published Medical Marketing And Media - Sep 16 2014]
Biogen/AbbVie Report Positive Data on MS Drug Z... [Published Yahoo! Finance - Sep 15 2014]
East Coast Biotech Roundup: Maraganore, Flex, N... [Published Xconomy - Sep 15 2014]
EBV and HHV-6 reactive cells concentrated in th... [Published Multiple Sclerosis Research - Sep 14 2014]
AbbVie, Biogen Announce Positive Phase III Resu... [Published Bidness Etc - Sep 12 2014]
Biogen Reports Positive Two-Year Data on MS Dru... [Published Zacks.com - Sep 12 2014]
AbbVie and Biogen inch toward the FDA with once... [Published FierceBiotech - Sep 12 2014]
Novel Drug Beats Avonex for MS Efficacy; Safety... [Published MedPageToday.com - medical news plus CME for ph ... - Sep 12 2014]
Detailed Results from Biogen Idec and AbbVie’s ... [Published Business Wire Photo/Multimedia News - Sep 12 2014]
Detailed Results from Biogen Idec and AbbVie’s ... [Published Business Wire News with Multimedia - Sep 12 2014]
Detailed Results from Biogen Idec and AbbVie’s ... [Published Business Wire Health News - Sep 12 2014]
5 Things Biogen Idec Inc's Management Wants You... [Published Motley Fool Discussion Boards - Sep 03 2014]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Aug 26 2014]
Hangout with us at ECTRIMS [Published Multiple Sclerosis Research - Aug 24 2014]
Politics: drug pricing [Published Multiple Sclerosis Research - Aug 24 2014]
NK cells are they important in MS [Published Multiple Sclerosis Research - Aug 18 2014]
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
The Launch of Five Immunomodulatory Therapies f... [Published PR Newswire: General Business - Aug 07 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ClinicSpeak: MS phenotypes by MRI [Published Multiple Sclerosis Research - Sep 20 2014]
Brain atrophy is ready for prime time: MRIologists need to sort-out the technology. #ClinicSpeak #MSBlog #MSResearch "The study below divides MSers into four categories based on two MRI metrics; (1) high or low T2 volumes, an integrator of focal inflammation ...
ECTRIMS 2014: Daclizumab results [Published Multiple Sclerosis Research - Sep 17 2014]
Daclizumab was my number 1 ECTRIMS highlight: what is it telling us about MS?  #MSBlog #MSResearch "My number one ECTRIMS highlight is the MRI daclizumab results, which shows that daclizumab reduces brain atrophy compared to Avonex in both year 1 and ...
Daclizumab HYP a new kid on the block [Published Multiple Sclerosis Research - Sep 16 2014]
Othman AA, Tran JQ, Tang MT, Dutta S. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration.  Clin Pharmacokinet. 2014 Sep 12. ...
EBV and HHV-6 reactive cells concentrated in th... [Published Multiple Sclerosis Research - Sep 14 2014]
Is MS caused by a virus? T cells reactive againts HHV-6 and EBV may provide a clue. #MSBlog #MSResearch "The study below suggests that T cells responding to specific herpes viruses are enriched in the spinal fluid of MSers and not T cells responding ...
Novel Drug Beats Avonex for MS Efficacy; Safety... [Published MedPageToday.com - medical news plus CME for ph ... - Sep 12 2014]
BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head ag ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.